Earnings ·
Kiora Pharmaceuticals reported second quarter 2026 financial results and provided clinical updates
KPHMWKiora Pharmaceuticals Inc
Kiora Pharmaceuticals reported second quarter 2026 financial results and provided clinical updates. The company ended the quarter with approximately $16.8 million in cash and short-term investments, providing an operating runway into late 2028. Net loss was approximately $2.1 million, compared to a net loss of $2.2 million in the prior year period. Research and development expenses were approximately $2.1 million before recognizing $1.3 million in reimbursable collaboration credits from Théa Open Innovation. The company secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront. Clinically, Kiora advanced enrollment in the Phase 2 ABACUS-2 trial of KIO-301 into the higher-dose cohort and continued enrollment in the Phase 2 KLARITY trial of KIO-104. The company operates as a clinical-stage biotechnology firm developing small-molecule therapies for retinal diseases.